Product Description
ALPS12 is the first next-generation T-cell redirecting antibody applying Chugai's proprietary Dual-Ig® technology. T-cell redirecting antibody (TRAB™) is designed to guide T cells to the target cancer cells by activating and engaging T cells through its binding to CD3 on T cells. One of its challenges, however, is that it has limited antitumor killing ability against poorly T-cell infiltrated tumors. Dual-Ig® is a novel technology providing antibodies with the ability to induce CD137 signalling, a co-stimulating molecule, in addition to CD3 signalling. This property potentially results in more potent antitumor effect against poorly T-cell infiltrated tumors than conventional T-cell engagers. (Sourced from: https://www.chugai-pharm.co.jp/english/ir/product/pipeline.html)
Mechanisms of Action: 4-1BB Inhibitor, CD3 Inhibitor
Novel Mechanism: Yes
Modality: Bispecific Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Hoffmann-La Roche
Company Location:
Company Founding Year: 1896
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Hong Kong, Japan, Taiwan
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Small Cell Lung Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07107490 |
ALP102CT | P1 |
Recruiting |
Small Cell Lung Cancer |
2028-09-30 |
50% |
2025-11-25 |
|
jRCT2031250274 |
jRCT2031250274 | P1 |
Not yet recruiting |
Small Cell Lung Cancer |
2028-09-30 |
Recent News Events
Date |
Type |
Title |
|---|